Pharmaceutical Executive July 28, 2021
Bernie Zeiher, Brand Insights Contributor, Chief Medical Officer, Astellas Pharma Inc.

In the last 18 months, clinical research has experienced momentous change. We have been challenged by the reality of research delays and halted programs—while simultaneously rising to meet the needs of patients—to maintain trial continuity and apply science to overcome global health problems.

As an industry, we should be proud. Not just that we’ve navigated this research paradox and its difficulties, but that ingenuity is now realizing important benefits for future trial design and for patients. Yet, there is more to be done. We’re now at an important inflection point in the industry’s approach to trial design and we must ask ourselves: How do we take forward everything we have learned and embrace this important step change while maintaining the...

Today's Sponsors

Transcarent
SalesSparx
Canton & Company

Today's Sponsors

Oscar
Curation Health

Today's Sponsor

TripleTree

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Rune Labs Lands $22.8M to for Neurology Precision Medicine Platform
Getting strategic about new-product submissions in the pharma industry
Venture firms warn R&D funding for new drugs will 'drop off a cliff' if Dem bill approved
Contentious report suggests safety net hospitals leveraging discounts to pocket strong gains from cancer drugs
Adrian Cheng Moves Deeper Into Healthcare Industry With Artisan Merger Of Prenetics At $1.2 Bln Valuation